Your institution may have access to this item. Find your institution then sign in to continue.
Title
A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer.
Authors
Schelman, William R; Liu, Glenn; Wilding, George; Morris, Thomas; Phung, De; Dreicer, Robert
Abstract
To assess the maximum well-tolerated dose (MWTD), dose limiting toxicity (DLT), pharmacokinetics (PK) and pharmacodynamics of zibotentan, a novel specific endothelin-A receptor antagonist, in patients with metastatic prostate cancer.
Publication
Investigational new drugs, 2011, Vol 29, Issue 1, p118